Modern Features and Particular Issues of Rotavirus Preventive Vaccination
Marina V. Fedoseenko,
Tatiana A. Kaiiuzhnaia,
Firuza Ch. Shakhtakhtinskaya,
Svetiana V. Tolstova,
Arevaiuis M. Selivyan https://doi.org/10.15690/pf.v21i6.2829
Abstract
Rotavirus is recognized as one of the worid’s most common pathogens of acute gastroenteritis among children (up to 5 years of age) and has significant impact on chiidhood morbidity and mortality. The recommended by WHO routine vaccination of infants against rotavirus infection has led to notable reduction in incidence, hospitalization and costs associated with rotavirus infection outcomes in countries that have achieved high vaccination coverage. However, we should be aware of several features of rotavirus vaccines implementation as their safety and efficacy depend on it. Despite the absence of rotavirus vaccination within the National Immunization Schedule in Russian Federation and extremely low coverage of rotavirus preventive vaccination, the authors receive many questions from practicing pediatricians regarding cases of rotavirus vaccination. This article includes complete answers for most relevant of them that arise during practical use of rotavirus vaccines.
Supporting agencies: The article has been prepared with the support of Pharm Aid LLC.
About the Authors
Marina V. Fedoseenko
Research institute of Pediatrics and Chiidren’s Health in Petrovsky National Research Centre of Surgery;
Pirogov Russian National Research Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Marina V. Fedoseenko, MD, PhD
10, Fotievoy Str., building I, Moscow, 119333
Disclosure of interest:
Not declared
Tatiana A. Kaiiuzhnaia
Research institute of Pediatrics and Chiidren’s Health in Petrovsky National Research Centre of Surgery;
Pirogov Russian National Research Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Tatiana А. Kaiiuzhnaia, MD, PhD
Moscow
Disclosure of interest:
Not declared
Firuza Ch. Shakhtakhtinskaya
Research institute of Pediatrics and Chiidren’s Health in Petrovsky National Research Centre of Surgery;
Pirogov Russian National Research Medical University
Russian Federation
Disclosure of interest:
Russian Federation
Firuza Ch. Shakhtakhtinskaya, MD, PhD
Moscow
Disclosure of interest:
Not declared
Svetiana V. Tolstova
Research institute of Pediatrics and Chiidren’s Health in Petrovsky National Research Centre of Surgery
Russian Federation
Disclosure of interest:
Russian Federation
Svetiana V. Tolstova, MD
Moscow
Disclosure of interest:
Not declared
Arevaiuis M. Selivyan
Research institute of Pediatrics and Chiidren’s Health in Petrovsky National Research Centre of Surgery
Russian Federation
Disclosure of interest:
Russian Federation
Arevaiuis М. Seivyan, MD
Moscow
Disclosure of interest:
Not declared
References
1. Wang J, Zhang H, Zhang H, Fang H. Public health impact and costeffectiveness of rotavirus vaccination in China: Comparison between private market provision and national immunization programs. Hum Vaccin Immunother. 2022;18(7):2090162. https://doi.org/10.1080/21645515.2022.2090162
2. WHO. Rotavirus. In: World Health Organization: Official website. Available online: https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/norms-and-standards/vaccines-quality/rotavirus. Accessed on November 15, 2024.
3. Troeger C, Khalil IA, Rao PC, et al. Rotavirus Vaccination and the Global Burden of Rotavirus Diarrhea Among Children Younger Than 5 Years. JAMA Pediatr. 2018;172(10):958–965. https://doi.org/10.1001/jamapediatrics.2018.1960
4. Clark A, Black R, Tate J, et al. Estimating global, regional and national rotavirus deaths in children aged <5 years: Current approaches, new analyses and proposed improvements. PLoS One. 2017;12(9):e0183392. https://doi.org/10.1371/journal.pone.0183392
5. LeClair СЕ, McConnell КА. Rotavirus. [Updated 2023 Jan 2]. In: StatPearls [lnternet]. Treasure lsland (FL): StatPearls Pubishing; 2023.
6. Skansberg A, Sauer M, Tan M, et al. Product review of the rotavirus vaccines ROTASIIL, ROTAVAC, and Rotavin-M1. Hum Vaccin Immunother. 2021;17(4):1223–1234. https://doi.org/10.1080/21645515.2020.1804245
7. O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossiiskoi Federatsii v 2023 godu: State report. Moscow: Federal Service for Supervision of Consumer Rights Protection and Human Behavior; 364 p. (In Russ).
8. Bencina G, Costantino C, Mameli C, et al. Real-world impact of rotavirus vaccination in European healthcare settings: a systematic literature review. Expert Rev Vaccines. 2022;21(8):1121–1136. https://doi.org/10.1080/14760584.2022.2075851
9. Agoti CN, Curran MD, Murunga N, et al. Differences in epidemiology of enteropathogens in children preand post-rotavirus vaccine introduction in Kilifi, coastal Kenya. Gut Pathog. 2022:14:32. https://doi.org/10.1186/sl3099-022-00506-z
10. Rotavirus vaccines: WHO position paper — July 2021. Weekly Epidemiological Record. 2021:96(28):301-219. Available online: https://iris.who.int/bitstream/handle/10665/342905/WER9628-301-319-eng-fre.pdf?sequence=l. Accessed on November 16,2024.
11. Vaccine Data Explorer: Rotavirus Vaccine (Rota). In: VIEW-hub by IVAC. Available online: https://view-hub.org/vaccine/rota. Accessed on November 16, 2024.
12. Rotavirusnaya infektsiya: А guide for doctors. Baranov AA, Namazova-Baranova LS, eds; Union of Pediatricians of Russia. 3rd edn., rev. and add. Moscow: Pediatr; 2023. 56 p. (In Russ).
13. Korovkin AS, Ignatyev GM. Results and prospects of rotavirus immunisation in the Russian Federation. Biological Products. Prevention, Diagnosis, Treatment. 2023;23(4):499-512. (In Russ), https://doi.org/10.30895/2221-996X-2023-23-4-499-512
14. Kulkami PS, Desai S, Tewari T, etal. Arandomized Phase III clinical trial to assess the efficacy of a bovine-human reassortantpentavalent rotavirus vaccine in Indian infants. Vaccine. 2017;35(45):6228-6237. https://doi.org/10.1016/J.vaccine.2017.09.014
15. PRota-V-Eid: drug label. Registration certificate No. ЛП-23514. Registration date: June 21, 2021. In: State Register of Medicines: Official website. (In Russ)]
16. Jain S, Haydel MJ. Child Intussusception. 2023Apr 10. In: StatPearIs [Internet]. Treasure Island (FL): StatPearIs Publishing; 2023.
17. Burnett E, Parashar U, Tate J. Rotavirus Vaccines: Effectiveness, Safety, and Future Directions. Paediatr Drugs. 2018;20(3):223-233. https://doi.org/10.1007/s40272-018-0283-
18. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and effieaey of an attenuated vaeeine against severe rotavirus gastroenteritis. N EngIJ Med. 2006;354(l):ll-22. https://doi.org/10.1056/NEJMoa052434
19. Vesikari T, Matson DO, Dennehy R et al. Safety and effieaey of a pentavalent human-bovine (WC3) reassortant rotavirus vaeeine. N Engl J Med. 2006;354(l):23-33. https://doi.org/10.1056/NEJMoa052664
20. Patel MM, Haber R Baggs J, etal. Intussuseeption and rotavirus vaeeination: a review of the available evidenee. Expert Rev Vaccines. 2009;8(11):1555-1564. https://doi.org/10.1586/erv.09.106
21. Kim KY, Kim DS. Relationship between Pentavalent Rotavirus Vaeeine and lntussuseeption: A Retrospeetive Study at a Single Center in Korea. Yonsel Med J. 2017;58(3):631-636. https://doi.org/10.3349/ymj.2017.58.3.631
22. Cho HK, Hwang SH, Nam HN, et al. Ineidenee of lntussuseeption before and after the introduetion of rotavirus vaeeine in Korea. PLoS One. 2020;15(8):e0238185. https://doi.org/10.1371/Journal.pone.0238185
23. World Health Organization. Weekly Epidemiologieal Reeord, 2009,vol.84,23 [full issue]. Weekly EpldemloIogIcaI Record = Relevć epidemlologique hebdomadalre. 2009;84(23):213-236. https://apps.who.int/iris/handle/10665/241346
24. Rotavirus vaeeines. WHO position paper — January 2013. Wkly Epidemiol Rec. 2013;88(5):49-64.
25. RotaTeq: drug label. Registration certificate No. ЛП-001865. Registration date: October 01, 2012. In: State Register of Medieines: Official website. (In Russ).] Доcтупно no: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=20e71417-2el4-4301-8f0d-86adf899e2e5. Сеылка активна на 16.11.2024.
26. Clark A, Tate J, Parashar U, et al. Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules.. Lancet Glob Health. 2019;7(ll):el541-el552. https://doi.org/10.1016/S2214-109X(19)30412-7
27. Baranov AA, Namazova-Baranova ES, Belyaeva IA, et al. Immunoprophylaxis of infectious diseases in premature infants. Pediatricheskaya farmakologiya — Pediatric pharmacolog — Pediatric pharmacology. 2018;15(5):376-389. (In Russ), https://doi.org/10.15690/pf.vl5i5.1960
28. Roue JM, Nowak E, Le Gal G, et al. Impact of rotavirus vaccine on premature infants. Clin Vaccine Immunol. 2014;21(10):1404-1409. https://doi.org/10.1128/CVI.00265-14
29. Florinskaya ЕВ, Keshishyan ES. Immunization of preterm infants. Rossiyskiy Vestnik Perinatologii i Pediatrii = Russian Bulletin of Perinatology and Pediatrics. 2021;66:(6):6-16. (In Russ), https://doi.org/10.21508/1027-4065-2021-66-6-6-1]
30. Kroger A, Bahta L, Long S, Sanchez R General Best Practice Guidelines for Immunization. Available online: www.cdc.gov/ vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf. Accessed on November 16, 2024.
31. Cortese MM, Haber R Chapter 19: Rotavirus. In: The Epidemiology and Prevention of Vaccine-Preventable Diseases: Course Textbook. 14th edn. 2021. Available online: https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-19-rotavirus.html. Accessed on November 16, 2024.
32. Rotavirus vaccines: Canadian Immunization Guide. In: Government in Canada. Available online: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-19-rotavirus-vaccine.html#p4cl8a5. Accessed on November 16, 2024.
33. Rotavirus. In: Immunisation Handbook-2024. Version 6. Available online: https://www.tewhatuora.govt.nz/for-health-professionals/clinical-guidance/immunisation-handbook/20-rotavirus. Accessed on November 16, 2024.
34. Vaccination for preterm infants. Rotavirus vaccine, In: The Australian Immunisation Handbook. Available online: https://immunisationhandbook.health.gov.au/contents/vaccination-forspecial-risk-groups/vaccination-for-preterm-infants#rotavirusvaccine Accessed on November 16, 2024.
35. Rotaviren (RV). in: Epldemlologlsches Bulletin. 2023;(4):25. Avaiiabie oniine: https://www.rki.de/DE/Content/infekt/EpidBuii/Archiv/2023/Ausgaben/04_23.pdf?biob=pubiicationFiie. Accessed on November 16, 2024.
36. Vaccination de L'enfant & de L'adolescent. Vaccination du prćmaturć. Revision 2013. Avaiiabie oniine: https://www.heaith.beigium.be/sites/defauit/fiies/upioads/fieids/fpsheaith_theme_fiie/19090255/Vaccination%20du%20pr%C3%A9matur%C3%A9%20-%20enfants%20et%20adoiescents%20-%20r%C3%A9vision%202013.pdf. Accessed on November 16, 2024.
37. Generai immunization procedures, in: NIAC immunization Guidelines. Royai Coiiege of Physicians of ireiand. Avaiiabie oniine: https://www.hse.ie/eng/heaith/immunisation/hcpinfo/iatentrant.pdf. Accessed on November 16, 2024.
38. Immunoprofllaktlka Infektslonnykh boleznel и nedonoshennykh deter. Ciinicai guideiines. Baranov AA, Namazova-Baranova LS, Beiyaeva ІА, et ai., eds. Moscow: Pediatr; 2019. 52 p. (In Russ)]
39. Hofstetter AM, Lacombe K, Klein EJ, et al. Risk of Rotavirus Nosocomial Spread After Inpatient Pentavalent Rotavirus Vaccination. Pediatrics. 2018:141(l):e20171110. https://doi.org/10.1542/peds.2017-1110
40. Dennehy PH, Vesikari T, Matson DO, et al. Efficacy of the pentavalent rotavirus vaccine, RotaTeq (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen). Hum Vaccin. 2011;7(5):563-568. https://doi.org/10.4161/ hv.7.5.15406
41. Grimwood K, Lambert SB, Milne RJ. Rotavirus Infections and Vaccines. Pediatr Drugs. 2010;12(4):235-256. https://doi.org/10.2165/11537200-000000000-00000
42. Interchangeabie medicinai products (clause 4, part 4, article 3 of the Federal Law of 27.12.2019 No. 475-ФЗ, clause 8 of the Government Resolution of 05.09.2020 No. 1360) (In Russ).] Доступно no: https://grls.rosminzdrav.ru/Forum/Files/243339/Perechen%20VZ%20(25.05.2022).xls. Ссылка активна на 15.11.2024.
43. Clark A, van Zandvoort K, Flasche S, et al. Efficacy of live oral rotavirus vaccines by duration of follow-up: a meta-regression of randomised controlled trials.. Lancet infect Dis. 2019;19(7):717-727. https://doi.org/10.1016/S1473-3099(19)30126-4
44. Vashishtha VM, Kumar R The durability of vaccine-induced protection: an overview. Expert Rev Vaccines. 2024;23(l):389-408. https://doi.org/10.1080/14760584.2024.2331065
45. Phua KB, Lim FS, Lau YL, et al. Rotavirus vaccine RIX4414 effieaey sustained duringthe third year of life: a randomized clinical trial in an Asian population. Vaccine. 2012;30(30):4552-4557. https://doi.org/10.1016/J.vaccine.2012.03.030
46. Vesikari T, Karvonen A, Ferrante SA, et al. Efficacy of the pentavalent rotavirus vaccine, RotaTeq, in Finnish infants up to 3 years of age: the Finnish extension study. Eur J Pediatr. 2010;169(11):1379-1386. https://doi.org/10.1007/s00431-010-1242-3
47. Zlamy M, Kofler S, Orth D, et al. The impact of Rotavirus mass vaccination on hospitalization rates, nosocomial Rotavirus gastroenteritis and secondary blood stream infections. BMC infect Dis. 2013:13:112. https://doi.org/10.1186/1471-2334-13-112
48. Maguire JE, Glasgow K, Glass K, et al. Rotavirus Epidemiolog and Monovalent Rotavirus Vaccine Effectiveness in Australia: 2010-2017. Pediatrics. 2019;144(4):e20191024. https://doi.org/10.1542/peds.2019-1024
49. Huang YC, Wu FT, Huang YC, et al. Long-term effectiveness of pentavalent and monovalent rotavirus vaccines against hospitalization in Taiw/an children. Vaccine. 2020;38(41):6435-6441. https://doi.org/10.1016/j.vaccine.2020.07.067
50. Pereira R Vetter V, Standaert B, Benninghoff B. Fifteen years of experience with the oral live-attenuated human rotavirus vaccine: reflections on lessons learned. Expert Rev Vaccines. 2020;19(8):755-769. https://doi.org/10.1080/14760584.2020.1800459
51. Middleton BF, Danchin M, Fathima P, et al. Review/ of the health impact of the oral rotavirus vaccine program in children under 5 years in Australia: 2006-2021. Vaccine. 2023;41(3):636-648. https://doi.0rg/lO.lOl6/J.vaccine.2022.12.008
Review
For citations:
Fedoseenko M.V., Kaiiuzhnaia T.A., Shakhtakhtinskaya F.Ch., Tolstova S.V., Selivyan A.M. Modern Features and Particular Issues of Rotavirus Preventive Vaccination. Pediatric pharmacology. 2024;21(6):516-524. (In Russ.) https://doi.org/10.15690/pf.v21i6.2829
Views:
220
Email this article 